Cargando…

Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?

BACKGROUND: The aim of this study was to assess and compare the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and the Choi criteria in evaluating the early response of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) treated with sunitinib. METHODS: Eightee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Yanji, Chen, Jie, Huang, Kun, Lin, Yuan, Chen, Minhu, Xu, Ling, Li, Zi-Ping, Feng, Shi-Ting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324282/ https://www.ncbi.nlm.nih.gov/pubmed/28231773 http://dx.doi.org/10.1186/s12885-017-3150-7

Ejemplares similares

Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
por: Solis-Hernandez, Mª Pilar, et al.
Publicado: (2019)

Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT
por: Zwirtz, Kevin, et al.
Publicado: (2022)

Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm
por: Wang, Yuhong, et al.
Publicado: (2018)

Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria
por: Sandvik, O. M., et al.
Publicado: (2015)

Combined Volumetric and Density Analyses of Contrast-Enhanced CT Imaging to Assess Drug Therapy Response in Gastroenteropancreatic Neuroendocrine Diffuse Liver Metastasis
por: Wang, Yi, et al.
Publicado: (2018)

Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms
por: Fang, Cheng, et al.
Publicado: (2017)

New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
por: Yin, Feng, et al.
Publicado: (2022)

Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Mafficini, Andrea, et al.
Publicado: (2019)

An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
por: Fang, Jiayun M, et al.
Publicado: (2022)

Advances in the imaging of gastroenteropancreatic neuroendocrine neoplasms
por: Ramachandran, Anupama, et al.
Publicado: (2022)

Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China
por: Fang, Cheng, et al.
Publicado: (2017)

Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors
por: Wang, Yuhong, et al.
Publicado: (2017)

Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models
por: Kawasaki, Kenta, et al.
Publicado: (2018)

Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot
por: Fernandez, Cornelius J, et al.
Publicado: (2021)

RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study
por: Lucidarme, Olivier, et al.
Publicado: (2019)

Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021)

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
por: Ali, Abir Salwa, et al.
Publicado: (2020)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

The Role of Dual-Energy CT for the Assessment of Liver Metastasis Response to Treatment: Above the RECIST 1.1 Criteria
por: Reginelli, Alfonso, et al.
Publicado: (2023)

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
por: Costelloe, Colleen M., et al.
Publicado: (2010)

The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine Neoplasms
por: Xu, Shuaishuai, et al.
Publicado: (2022)

Assessment and State of Nutrition of Patients with Gastroenteropancreatic Neuroendocrine Neoplasms
por: Kikut, Justyna, et al.
Publicado: (2020)

Inflammation-related cytokines and their roles in gastroenteropancreatic neuroendocrine neoplasms
por: Mahečić, Davorka Herman, et al.
Publicado: (2020)

Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland
por: Alwan, Heba, et al.
Publicado: (2020)

The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
por: Venizelos, Andreas, et al.
Publicado: (2021)

Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms
por: Takayanagi, Daisuke, et al.
Publicado: (2022)

Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
por: Dai, Meng, et al.
Publicado: (2022)

Inflammation Related to Obesity in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Budek, Marlena, et al.
Publicado: (2022)

Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms
por: Yao, Hailing, et al.
Publicado: (2023)

Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Adnan, Aadil, et al.
Publicado: (2023)

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
por: van der Veldt, A A M, et al.
Publicado: (2010)

Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm
por: Shi, Huiying, et al.
Publicado: (2020)

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
por: Sato, Yozo, et al.
Publicado: (2013)

Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology
por: Kidd, Mark, et al.
Publicado: (2015)

Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Alexandraki, Krystallenia I., et al.
Publicado: (2017)

Neuroendocrine neoplasms: a brief overview emphasizing gastroenteropancreatic tumors
por: Lopes, José Manuel
Publicado: (2017)

SUN-302 Incidence Trends in Lung and Gastroenteropancreatic Neuroendocrine Neoplasms
por: Alwan, Heba, et al.
Publicado: (2020)

Current status of surgical management of patients with gastroenteropancreatic neuroendocrine neoplasms
por: Stankiewicz, Rafał, et al.
Publicado: (2022)

Diagnostic work-up and advancement in the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
por: Koffas, Apostolos, et al.
Publicado: (2023)

Site‐specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany
por: Grundmann, Nina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rlt405qm5n4bptn31laqtap092